Breaking News: AbbVie Files Complaint Against Amgen

AbbVie v. Amgen (adalimumab)  •  U.S. Biosimilar Litigation News

AbbVie has filed a complaint against Amgen related to AbbVie’s Humira (adalimumab).  The complaint asserts patent infringement and also seeks a declaratory judgment to compel Amgen to comply with the BPCIA’s notice of commercial marketing provision.

Stay tuned to Big Molecule Watch for more details later today.

Download PDF

Comments are closed.